Alkem Labs gets EIR report from US FDA
Alkem Laboratories has received an Establishment Inspection Report from the US Food and Drug Administration for its manufacturing facility at Amaliya24-07-2018
24-07-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
In furtherance to the intimation captioned "US FDA Inspection at Alkem's manufacturing facility located at Amaliya, Daman" dated 28th March, 2018, this is to inform you that US FDA has issued an Establishment Inspection Report (EIR) for the Company's manufacturing facility located at Amaliya, Daman, India which was inspected from 19th March, 2018 to 27th March, 2018....24-07-2018
Shareholding for the Period Ended June 30, 2018
Alkem Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2018. For more details, kindly Click here10-07-2018
Statement Of Investor Complaints For The Quarter Ended June 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Manish NarangDesignation :- Company Secretary and Compliance Officer09-07-2018
Board Meeting-Closure of Trading Window
This is to inform you that in terms of Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window will remain closed from 29th June, 2018 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter ended 30th June, 2018 are communicated to the Stock Exchanges.28-06-2018
Board Meeting-Closure of Trading Window
Intimation of Opening of Trading Window We refer to our earlier communication dated 28th March, 2018 regarding closure of trading window (for the purpose of financial results for the quarter and year ended 31st March 2018) starting from 30th March, 2018 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and year ended 31st March, 2018 are communicated to the Stock Exchanges....30-05-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release and Investor Presentation on Q4FY18 and FY18 Results30-05-2018
Fixes Record Date For The Purposes Of The Annual General Meeting And Payment Of Final Dividend
The Board of Directors at its meeting held today i.e. 30th May, 2018, has, inter alia fixed 24th August, 2018 as the record date for the purposes of the Annual General Meeting and payment of final dividend.30-05-2018
Corporate Action-Board approves Dividend
The Board of Directors at its meeting held today i.e. 30th May, 2018, has, inter alia 1. recommended a final dividend of Rs. 7/- (Rupees Seven only) per equity share of Rs. 2/- each for the financial year ended 31st March, 2018, for the approval of the shareholders of the Company at the ensuing Annual General Meeting. 2. approved 31st August, 2018 as the date of 44th Annual General Meeting of the Company....30-05-2018
Board recommends Final Dividend (AGM on August 31, 2018)
Alkem Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2018, inter alia, have recommended a final dividend of Rs. 7/- (Rupees Seven only) per equity share of Rs. 2/- each for the financial year ended March 31, 2018, for the approval of the shareholders of the Company at the ensuing Annual General Meeting.The dividend, if declared by the shareholders, shall be paid on and from September 04, 2018.30-05-2018